Implementation of risk sharing models in access to treatment of rare diseases: an integrative review
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (4)
Abstract
The objective of this integrative review was to identify the implementation of risk-sharing models in access to treatment for rare diseases in Brazil and the world. The chosen databases were: BVS - Biblioteca Virtual em Saúde, Embase, PubMed, and Scopus. After exclusions, 18 studies were included. The high cost of treatment and uncertainty regarding clinical evidence were observed as the primary barriers to access. Risk-sharing models are generally divided into financially-based models and performance-based models. It was noted that the implementation of these mechanisms widens access to technology that would probably not be available otherwise and highlights significant insights, such as the lack of transparency and standardization in implementation, resulting in inequity of access to orphan drugs. It is concluded that the implementation of these models minimizes financial and performance barriers, potentially expanding access to treatment for rare diseases. Transparency and the exchange of experiences between countries are crucial for the creation of policies and guidelines that make the process more effective in expanding access.Keywords
This publication has 23 references indexed in Scilit:
- Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in CanadaHealth Policy, 2024
- Financing and Reimbursement of Approved Advanced Therapies in Several European CountriesValue in Health, 2023
- Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain)Value in Health, 2022
- Access to medicines in Turkey: Evaluation of the process of medicines brought from abroadInternational Journal of Technology Assessment in Health Care, 2020
- Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in BelgiumEuropean Journal of Clinical Pharmacology, 2019
- A review of international coverage and pricing strategies for personalized medicine and orphan drugsHealth Policy, 2017
- Risk-Sharing Agreements in the EU: A Systematic Review of Major TrendsPharmacoEconomics - Open, 2017
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task ForceValue in Health, 2013
- Rare diseases: what's next?The Lancet, 2008
- Assessing the economic challenges posed by orphan drugsInternational Journal of Technology Assessment in Health Care, 2007